Patient diversity remains a problem in clinical trials. Although FDA-approved medicines serve a diverse population of Americans, participation in clinical trials remains predominantly white and male.
In this webinar segment, Cassandra Smith, director of diversity & inclusion in clinical trials for Janssen, discusses what it will take to move the needle on patient diversity. Smith believes solving the problem comes down to leading with humility and empathy. Drug developers need to understand where people are and what they need. Once you understand that, you can connect with them on a more human basis and understand what motivates and drives them. Only then can you have meaningful conversations about trial participation and the concerns patients have.